SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
May 11, 2012
|BIOANALYTICAL SYSTEMS, INC.|
|(Exact name of registrant as specified in its charter)|
|(State or other
||(Commission File Number)
||(I.R.S. Employer Identification No.)|
2701 KENT AVENUE
WEST LAFAYETTE, INDIANA
|(Address of principal executive offices)
Registrant's telephone number, including
area code: (765) 463-4527
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR240.14a-12)|
||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR240.14d-2(b))|
||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR240.13e-4(c))|
The information provided in Item 2.02 and
Item 9.01 of this Form 8-K is being furnished and shall not be deemed "filed" for the purpose of Section 18 of the Securities
Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in Item 2.02 and Item
9.01 of this Form 8-K shall not be incorporated by reference into any registration statement or other document pursuant to the
Securities Act of 1933, as amended.
Item 2.02. Results of Operations and Financial Condition.
On May 11, 2012, Bioanalytical Systems,
Inc. issued a press release announcing results for the first six months of fiscal 2012, ending March 31, 2012. The full text of
the press release is furnished as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(a) Not applicable.
(b) Not applicable.
(c) Not applicable.
99.1 Bioanalytical Systems, Inc. press
release, issued May 11, 2012.
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
||Bioanalytical Systems, Inc.|
|Date: May 11, 2012
||/s/ Jacqueline M. Lemke|
||Jacqueline M. Lemke|
||Vice President, Finance, Chief Financial Officer|
||Bioanalytical Systems, Inc. press release, issued May 11, 2012.|